Experts question Covaxin’s high private market price as R&D was govt subsidised

Experts have questioned the rationale of high prices of Covaxin since it is based on an established technology, is domestically-produced, and it’s R&D has been part-subsidised by the Centre. Other vaccines like polio and hepatitis B using a similar technology platform, are affordable due to large volumes and economies of scale, a strategy which should have been followed early-on in the case of Covaxin, they said.

from India News | Latest News Headlines & Live Updates from India - Times of India https://ift.tt/3vmXx5C